News Snapshot:
China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its Covid-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator. It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday. The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug. 11. ALSO READ: Malaysia detects new Covid-19 strain that's 10 times more infectious Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it...
